Risk of Recurrent Venous Thromboembolism in Patients With Common Thrombophilia: A Systematic Review | Genetics and Genomics | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Prandoni  PLensing  AWCogo  A  et al.  The long-term clinical course of acute deep venous thrombosis.  Ann Intern Med 1996;1251- 7PubMedGoogle ScholarCrossref
2.
Eichinger  SWeltermann  AMinar  E  et al.  Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism.  Arch Intern Med 2004;16492- 96PubMedGoogle ScholarCrossref
3.
Büller  HRAgnelli  GHull  RDHyers  TMPrins  MHRaskob  GE Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest 2004;126 ((3)(suppl)) 401S- 428SPubMedGoogle ScholarCrossref
4.
Kearon  C Long-term management of patients after venous thromboembolism.  Circulation 2004;110 ((suppl 1)) I10- I18PubMedGoogle ScholarCrossref
5.
Ost  DTepper  JMihara  HLander  OHeinzer  RFein  A Duration of anticoagulation following venous thromboembolism: a meta-analysis.  JAMA 2005;294706- 715PubMedGoogle ScholarCrossref
6.
Rees  DCCox  MClegg  JB World distribution of factor V Leiden.  Lancet 1995;3461133- 1134PubMedGoogle ScholarCrossref
7.
Rosendaal  FRDoggen  CJZivelin  A  et al.  Geographic distribution of the 20210 G to A prothrombin variant.  Thromb Haemost 1998;79706- 708PubMedGoogle Scholar
8.
De Stefano  VRossi  EPaciaroni  KLeone  G Screening for inherited thrombophilia: indications and therapeutic implications.  Haematologica 2002;871095- 1108PubMedGoogle Scholar
9.
Ridker  PMMiletich  JPStampfer  MJGoldhaber  SZLindpaintner  KHennekens  CH Factor V Leiden and risks of recurrent idiopathic venous thromboembolism.  Circulation 1995;922800- 2802PubMedGoogle ScholarCrossref
10.
Rintelen  CPabinger  IKnobl  PLechner  KMannhalter  C Probability of recurrence of thrombosis in patients with and without factor V Leiden.  Thromb Haemost 1996;75229- 232PubMedGoogle Scholar
11.
Eichinger  SPabinger  IStumpflen  A  et al.  The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.  Thromb Haemost 1997;77624- 628PubMedGoogle Scholar
12.
Simioni  PPrandoni  PLensing  AW  et al.  The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden).  N Engl J Med 1997;336399- 403PubMedGoogle ScholarCrossref
13.
De Stefano  VMartinelli  IMannucci  PM  et al.  The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.  N Engl J Med 1999;341801- 806PubMedGoogle ScholarCrossref
14.
Eichinger  SMinar  EHirschl  M  et al.  The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene.  Thromb Haemost 1999;8114- 17PubMedGoogle Scholar
15.
Lindmarker  PSchulman  SSten-Linder  M  et al.  The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene: duration of anticoagulation.  Thromb Haemost 1999;81684- 689PubMedGoogle Scholar
16.
Margaglione  MD'Andrea  GColaizzo  D  et al.  Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism.  Thromb Haemost 1999;821583- 1587PubMedGoogle Scholar
17.
Simioni  PPrandoni  PLensing  AW  et al.  Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis.  Blood 2000;963329- 3333PubMedGoogle Scholar
18.
De Stefano  VMartinelli  IMannucci  PM  et al.  The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation.  Br J Haematol 2001;113630- 635PubMedGoogle ScholarCrossref
19.
Miles  JSMiletich  JPGoldhaber  SZHennekens  CHRidker  PM G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism.  J Am Coll Cardiol 2001;37215- 218PubMedGoogle ScholarCrossref
20.
Christiansen  SCCannegieter  SCKoster  TVandenbroucke  JPRosendaal  FR Thrombophilia, clinical factors, and recurrent venous thrombotic events.  JAMA 2005;2932352- 2361PubMedGoogle ScholarCrossref
21.
Machin  SJ Pros and cons of thrombophilia testing: cons.  J Thromb Haemost 2003;1412- 413PubMedGoogle ScholarCrossref
22.
Martinelli  I Pros and cons of thrombophilia testing: pros.  J Thromb Haemost 2003;1410- 411PubMedGoogle ScholarCrossref
23.
Mantel  NHaenszel  W Statistical aspects of the analysis of data from retrospective studies of disease.  J Natl Cancer Inst 1959;22719- 748PubMedGoogle Scholar
24.
Higgins  JPThompson  SGDeeks  JJAltman  DG Measuring inconsistency in meta-analyses.  BMJ 2003;327557- 560PubMedGoogle ScholarCrossref
25.
Deeks  JJedHiggins  JPTedAltman  DGed Analysing and presenting results. Alderson  PGreen  SHiggins  Jeds Cochrane Reviewers' Handbook 4.2.2 [updated November 2004]; Section 8. Available at: http://www.cochrane.org/resources/handbook/hbook.htm. Accessed March 23, 2005Google Scholar
26.
Ridker  PM Factor V Leiden and recurrent venous thromboembolism.  Thromb Haemost 1996;76815- 816PubMedGoogle Scholar
27.
Schattner  AKasher  IBerrebi  A Causes and outcome of deep-vein thrombosis in otherwise-healthy patients under 50 years.  QJM 1997;90283- 287PubMedGoogle ScholarCrossref
28.
Baglin  CBrown  KLuddington  RBaglin  TEast Anglian Thrombophilia Study Group, Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors.  Br J Haematol 1998;100764- 768PubMedGoogle ScholarCrossref
29.
Kearon  CGent  MHirsh  J  et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.  N Engl J Med 1999;340901- 907PubMedGoogle ScholarCrossref
30.
Piemontino  UGuiotto  GRugiada  FCirillo  FCerbone  AM Abnormally high frequency of inherited pro-thrombotic conditions in subjects with recurrence of venous thrombosis.  Thromb Haemost 1999;821359- 1360PubMedGoogle Scholar
31.
Eichinger  SWeltermann  AMannhalter  C  et al.  The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism.  Arch Intern Med 2002;1622357- 2360PubMedGoogle ScholarCrossref
32.
Keijzer  MBden Heijer  MBlom  HJ  et al.  Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis.  Thromb Haemost 2002;88723- 728PubMedGoogle Scholar
33.
Meinardi  JRMiddeldorp  Sde Kam  PJ  et al.  The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders.  Br J Haematol 2002;116625- 631PubMedGoogle ScholarCrossref
34.
Baglin  TLuddington  RBrown  KBaglin  C Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.  Lancet 2003;362523- 526PubMedGoogle ScholarCrossref
35.
Marcucci  RLiotta  AACellai  AP  et al.  Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism.  Am J Med 2003;115601- 605PubMedGoogle ScholarCrossref
36.
Palareti  GLegnani  CCosmi  B  et al.  Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.  Circulation 2003;108313- 318PubMedGoogle ScholarCrossref
37.
Procare Group, Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients?  Blood Coagul Fibrinolysis 2003;14523- 529PubMedGoogle ScholarCrossref
38.
Ridker  PMGoldhaber  SZDanielson  E  et al.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.  N Engl J Med 2003;3481425- 1434PubMedGoogle ScholarCrossref
39.
Spiezia  LBernardi  ETormene  DSimioni  PGirolami  APrandoni  P Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors.  Thromb Haemost 2003;90964- 966PubMedGoogle Scholar
40.
Kyrle  PAMinar  EBialonczyk  CHirschl  MWeltermann  AEichinger  S The risk of recurrent venous thromboembolism in men and women.  N Engl J Med 2004;3502558- 2563PubMedGoogle ScholarCrossref
41.
Kyrle  PAEichinger  S The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism.  Wien Klin Wochenschr 2003;115471- 474PubMedGoogle ScholarCrossref
42.
Schulman  SRhedin  ASLindmarker  P  et al. Duration of Anticoagulation Trial Study Group, A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism.  N Engl J Med 1995;3321661- 1665PubMedGoogle ScholarCrossref
43.
 Findings from the aspirin component of the ongoing Physicians' Health Study.  N Engl J Med 1988;318262- 264PubMedGoogle ScholarCrossref
44.
Schulman  SGranqvist  SHolmström  M  et al.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism.  N Engl J Med 1997;336393- 398PubMedGoogle ScholarCrossref
45.
Marchetti  MPistorio  ABarosi  G Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden–cost-effectiveness analysis.  Thromb Haemost 2000;84752- 757PubMedGoogle Scholar
46.
Vink  RKraaijenhagen  RALevi  MBüller  HR Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model.  J Thromb Haemost 2003;12523- 2530PubMedGoogle ScholarCrossref
Review
April 10, 2006

Risk of Recurrent Venous Thromboembolism in Patients With Common Thrombophilia: A Systematic Review

Author Affiliations

Author Affiliations: Department of Haematology, Royal Perth Hospital and Centre for Clinical Research Excellence (Dr Ho), Stroke Unit, Royal Perth Hospital and School of Medicine and Pharmacology (Dr Hankey), University of Western Australia, Perth; Department of Radiology, King's College Hospital, London, England (Dr Quinlan); and Department of Medicine, McMaster University, Hamilton, Ontario (Dr Eikelboom).

Arch Intern Med. 2006;166(7):729-736. doi:10.1001/archinte.166.7.729
Abstract

The 2 most common genetic polymorphisms that predispose to a first episode of venous thromboembolism (VTE) are factor V Leiden (FVL) and prothrombin G20210A. However, the effect of these polymorphisms on the risk of recurrent VTE is unclear. We performed a meta-analysis to obtain best estimates of the relative risk of recurrent VTE associated with these genetic polymorphisms. Electronic and manual searches were used to identify cohort studies of patients with a first episode of VTE that reported the incidence of objectively confirmed recurrence following discontinuation of anticoagulation among those with or without heterozygous FVL or prothrombin G20210A polymorphism. Thirteen reports fulfilled our criteria for inclusion. Pooled results from 10 studies involving 3104 patients with first-ever VTE revealed that FVL was present in 21.4% of patients (95% confidence interval [CI], 20%-23%) and associated with an increased odds of recurrent VTE of 1.41 (95% CI, 1.14-1.75; P = .08 for heterogeneity). Pooled results from 9 studies involving 2903 patients with first-ever VTE revealed that prothrombin G20210A was present in 9.7% of patients (95% CI, 9%-11%) and associated with an increased odds of recurrent VTE of 1.72 (95% CI, 1.27-2.31; P = .19). The estimated population-attributable risk of recurrence for FVL was 9.0% (95% CI, 4.5%-13.2%) and for prothrombin G20210A was 6.7% (95% CI, 3.4%-9.9%). Heterozygous FVL and prothrombin G20210A are each associated with a significantly increased risk of recurrent VTE after a first event, but the magnitude of the increase in risk is modest and by itself is unlikely to merit extended-duration anticoagulation. These data call into question the cost-effectiveness of routine testing for these common inherited thrombophilic polymorphisms among patients with a first episode of VTE.

×